A De-Escalating Strategy for Antibiotic Treatment of Pneumonia in The Medical Intensive Care Unit (0787B-092)

Phase 4

Completed

• Conditions: Infection; Pneumonia

• Registration Number: NCT00445094
• Lead Sponsor: Merck Sharp & Dohme LLC

Brief Summary

The primary objective of this study is a comparison between MK0787B and standard therapy.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design

Study Timeline

• Study Start: 2006-11
• Primary Completion: 2007-01
• Study Completion: 2007-01
• Study First Submitted: 2007-03-06
• Study First Submitted QC: 2007-03-06
• Study First Posted: 2007-03-08
• Status Verified: 2017-02
• Last Update Submitted: 2017-02-15
• Last Update Posted: 2017-02-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 120

Inclusion Criteria

• Greater than 18 years of age
• Patient is diagnosed with nosocomial pneumonia

Read More

Exclusion Criteria

• Immunological deficient patients
• Pregnant women and nursing mothers
• A fungus is identified before the study enrollment
• Received vancomycin or imipenem for more than 5 days before icu admission

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
A 30-day-survival rate in the intensive care unit evaluated by Acute Physiology and Chronic Health (APACH II) Disease Classification System II score